Articles by Abby Proch

  1. C-Suite Changes Help Biotech Narrow Focus But Maintain Drive To Treat Fatal Neonatal Brain Injury 8/5/2026

    Newly-appointed leaders at ReAlta Life Sciences discuss their skill sets, their goals for advancing a therapy for hypoxic ischemic encephalopathy (HIE), and how they keep momentum as they strive to help bring this potentially lifesaving therapy to market.

  2. From Signal To Strategy: What Oncology Basket Trials Can Teach Clinical Development Teams 7/29/2026

    AbbVie's Svetlana Kobina discusses how basket trials can help clinical development teams move from early clinical signals to a more disciplined strategy.

  3. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  4. Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients 7/24/2026

    CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.

  5. Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/20/2026

    CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

  6. What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory Confidence 7/17/2026

    Pistoia Alliance President Becky Upton, Ph.D., reviews findings from a poll about AI use in clinical research conducted at Clinical Trials Technology Congress (CTTC) that revealed barriers to adoption, early ROI, emerging use cases, and the role of patient-generated data.

  7. The Promise Of Bispecifics In The Quest For Outpatient Immunotherapy 7/15/2026

    START San Antonio's Drew Rasco, MD, reflects on the evolution of immunotherapy and highlights how novel therapies such as bispecifics are both challenging and intriguing for principal investigators (PIs).

  8. Digital Twins Enhance Disease Progression Measurements In FSHD 7/14/2026

    Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy. 

  9. Navigating The New EU Pharmaceutical Legislation: Key Implications For Pediatric Drug Development 7/13/2026

    UCB’s Senior Development Strategy Lead Pediatrics Martine Dehlinger-Kremer, Ph.D., discusses updates to the new EU Pharma legislation and how they impact pediatric drug development, including earlier pediatric investigational plans .

  10. i-Cubed Used End-To-End AI In A Proof-Of-Concept Trial. Here's What They Learned 7/2/2026

    Discover how well AI fared in document generation, patient engagement, data integration, and more in an end-to-end proof-of-concept study run by i-Cubed.